



# Biotech Daily

Friday June 26, 2009

*Daily news on ASX-listed biotechnology companies*

## **\* EUROPEAN DATASET SHOULD LEAD TO BIOPHARMICA COLLABORATION**

### **BIOPHARMICA**

Biopharmica says a Western European clinical trial dataset was expected to “lead to collaboration with a number of European centers of anaesthetic monitoring excellence”. Biopharmica chairman David Breeze told Biotech Daily that his company and its shareholders held a majority stake in Cortical Dynamics which received the comprehensive electronic dataset from a Western European clinical research centre. Mr Breeze said the electronic data was from a study which used the same design as Cortical Dynamics most recent opioid trial and was being analyzed with Cortical Dynamics brain anaesthesia response (BAR) analysis methodology.

In a media release to the ASX Biopharmica said the data sharing would “lead to collaboration with a number of European centers of anaesthetic monitoring excellence”. The company said that further validation of the results was expected to be completed in the fourth quarter of 2009.

Biopharmica said the Cortical Dynamics team was lead by Dr David Liley and had completed two clinical trials at the Royal Melbourne Hospital and the results from the first trial have been published in the journal ‘Computers in Biology and Medicine’.

Biopharmica said the trials proved scientific acceptance for the brain anaesthesia response (BAR) methodology and showed superiority over existing approaches.

The second trial was designed to evaluate the sensitivity of the BAR methodology to opioids and other intravenous anaesthetic drugs, studied 55 patients and was complete with results analyzed.

Biopharmica said both trials confirmed that the BAR algorithm was more sensitive than competitive monitors in detecting the anaesthetic drug effect.

The company said Cortical Dynamics’ BAR analysis was based on the physiological mechanisms that generate brain electrical activity allowing the BAR Monitor to be “faster, much more sensitive and accurate than existing monitors”.

Biopharmica said the program would trial the BAR’s sensitivity with the most commonly used anaesthetic drugs.

Investigation of the data over the last few months from both trials has highlighted a number of improvements for the BAR monitor, Biopharmica said.

The company said the sensor layout had been modified to increase the level of the brain electrical activity detected and the data acquisition module was “being fine-tuned to improve the BAR Monitors resilience to signal noise”.

The improvements were designed to increase the quality of the collected data.

Biopharmica said that improving the input signals would further enhance the sensitivity of the BAR Monitor’s ability to detect anaesthetic drug effects as well as increasing its robustness in dealing with an operating theatre and its electrical environment.

The upgraded Monitor is scheduled to be completed by October 2009.

Biopharmica was unchanged at 2.1 cents.